China goes ahead with Russian Cancer Vaccine ‘Enteromix’ that could dent profits of Pharma giants

2026-02-10 - 13:46

ISLAMABAD – China is reportedly considering approving a cancer vaccine developed by Russia, a breakthrough that has the potential to dent multi-billion-dollar pharma industry. Unlike conventional treatments that rely on long-term, expensive drug regimens, the vaccine is designed to train the immune system to identify and destroy cancer cells directly. Western pharmaceutical giants have long dominated the $225–$250 billion global oncology market, built on prolonged therapies. But if Russia’s vaccine proves scalable and effective, it could challenge decades of entrenched business models and redefine cancer care worldwide. The vaccine Enteromix has reportedly completed preclinical trials and is moving through Russia’s regulatory process. Early animal studies showed tumor reductions of 60% to 80%. A small Phase I human trial involving 48 participants focused on immune system activation, though results have not been published in peer-reviewed journals. Claims of “100% efficacy” in Russian media refer solely to immune response, and not actual cancer cure. Initially developed for colorectal cancer, Enteromix is now being explored for glioblastoma and ocular melanoma. While these early results are promising, larger independent studies are needed to verify safety, dosage, and therapeutic impact. While Russia and China have general healthcare cooperation agreements, no official partnership on Enteromix has been confirmed. Yet China’s growing biotech sector and openness to non-Western platforms make the possibility of collaboration a story worth watching. If proven effective, Enteromix could drastically reduce dependency on long-term drug treatments, offering a new hope to millions. Colorectal cancer alone accounted for nearly 2 million new cases globally in 2020. However, for now, the vaccine remains unavailable internationally, with no regulatory approvals outside Russia and no large-scale trials confirming its safety or efficacy. Russia has suggested it could provide Enteromix free to its citizens at roughly $3,800 per dose, but global adoption will hinge on patent laws, regulatory approvals, and manufacturing standards. The vaccine represents a potential disruptor in a field already being transformed by immunotherapies such as CAR-T cells and checkpoint inhibitors. Enteromix has not entered Phase II or III trials, and independent verification is lacking, with more details awaited. With countries like Russia and China advancing in biotech, patients could see groundbreaking therapies emerging from unexpected corners of the globe. Pakistan set to introduce HPV vaccine to prevent cervical cancer